Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
We conducted a national, single center (Hospital Clínico Universitario de Valladolid, Spain, Valladolid), prospective study of patients with prior hospitalization because of COVID-19 who were admitted between March 1st, 2020, and May 15th, 2020. All eligible patients underwent at least at first-time follow-up from the index event. Exclusion criteria were age < 18 years old, pregnant women, terminally ill patients, active SARS-CoV-2 infections, inability to exercise and previous known severe pulmonary or heart disease. Patients underwent a clinical assessment for symptom burden, questionnaire for quality of life (Kansas City Cardiomyopathy Questionnaire and SF-36), venous blood sampling, 6-minute walking test (6-MWT), tests of lung function (spirometry and diffusing capacity of the lungs for carbon monoxide) and treadmill cardio-pulmonary exercise testing (CPET). 48-hours before the test of lung function and the CPET, all patients yielded a negative result in the reverse transcription-polymerase chain reaction (RT-PCR) for SARS-CoV-2. For definitive analysis patients were assigned to the control group if they did not refer dyspnea at the time of the follow-up, a small asymptomatic out-patient control group without prior hospitalization was also included.
Description: Measured as peak oxygen uptake
Measure: Aerobic capacity Time: 6 monthsDescription: Pulmonary function test
Measure: Total Lung Capacity (TLC) Time: 6 monthsDescription: Pulmonary function test
Measure: Force Expiratory Volume in 1 second (FEV1) Time: 6 monthsDescription: Pulmonary function test
Measure: Difussing Lung Capacity of CO (DLCO) Time: 6 monthsDescription: Pulmonary function test
Measure: Forced Vital Capacity (FVC) Time: 6 monthsDescription: Left Ventricular (LV) Function (Ecocardiagraphy-measured Cardiac Function)
Measure: Left Ventricular (LV) Function Time: 6 monthsDescription: Right Ventricular (RV) Function (Ecocardiagraphy-measured Cardiac Function)
Measure: Right Ventricular (RV) Function Time: 6 monthsDescription: Quality of Life test
Measure: Short Form 36 Health Survey (SF-36) Time: 6 monthsDescription: Quality of Life test
Measure: Kansas City Cardiomyopathy Questionnaire (KCCQ) Time: 6 MonthsDescription: Walking capacity
Measure: 6 Minute Walk Test Time: 6 monthsDescription: Inflammatory and Cardiac Marker
Measure: N-terminal pro hormone B-type natriuretic peptide (NT-proBNP) Time: 6 monthsDescription: Inflammatory and Cardiac Marker
Measure: Troponin-T Time: 6 monthsDescription: Inflammatory and Cardiac Marker
Measure: Ferritin Time: 6 monthsDescription: Inflammatory and Cardiac Marker
Measure: D-Dimer Time: 6 monthsDescription: Inflammatory and Cardiac Marker
Measure: interleukine-6 Time: 6 monthsDescription: Inflammatory and Cardiac Marker
Measure: C reactive protein (CRP) Time: 6 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports